For example, omalizumab has entered clinical practice for the treatment of moderate to severe persistent asthma in individuals with documented allergy to a perennial aeroallergen, and with serum IgE levels between 30 and 700 IU/ml (Fanta, 2009). This evidence concerns the gene IGHE and allergic disease.